' Akciju kurss '

Datums	Shanghai Pharmaceuticals Holding Co Apgrozījums	Shanghai Pharmaceuticals Holding Co EBIT	Shanghai Pharmaceuticals Holding Co Peļņa
2026e	357,23 miljardi undefined	12,63 miljardi undefined	3,50 miljardi undefined
2025e	322,76 miljardi undefined	11,21 miljardi undefined	3,04 miljardi undefined
2024e	291,16 miljardi undefined	9,86 miljardi undefined	2,70 miljardi undefined
2023	260,30 miljardi undefined	8,86 miljardi undefined	3,77 miljardi undefined
2022	231,98 miljardi undefined	8,32 miljardi undefined	5,62 miljardi undefined
2021	215,82 miljardi undefined	7,80 miljardi undefined	5,09 miljardi undefined
2020	191,91 miljardi undefined	7,74 miljardi undefined	4,50 miljardi undefined
2019	186,57 miljardi undefined	7,37 miljardi undefined	4,08 miljardi undefined
2018	159,08 miljardi undefined	5,71 miljardi undefined	3,88 miljardi undefined
2017	130,85 miljardi undefined	5,06 miljardi undefined	3,52 miljardi undefined
2016	120,77 miljardi undefined	3,74 miljardi undefined	3,20 miljardi undefined
2015	105,52 miljardi undefined	3,62 miljardi undefined	2,88 miljardi undefined
2014	92,40 miljardi undefined	3,21 miljardi undefined	2,59 miljardi undefined
2013	78,22 miljardi undefined	2,79 miljardi undefined	2,24 miljardi undefined
2012	68,08 miljardi undefined	2,55 miljardi undefined	2,05 miljardi undefined
2011	54,90 miljardi undefined	2,34 miljardi undefined	2,04 miljardi undefined
2010	38,53 miljardi undefined	1,76 miljardi undefined	1,27 miljardi undefined
2009	31,26 miljardi undefined	1,28 miljardi undefined	1,30 miljardi undefined
2008	16,55 miljardi undefined	208,00 milj. undefined	82,00 milj. undefined
2007	13,92 miljardi undefined	220,00 milj. undefined	66,00 milj. undefined
2006	12,64 miljardi undefined	120,00 milj. undefined	-39,00 milj. undefined
2005	10,70 miljardi undefined	90,00 milj. undefined	51,00 milj. undefined
2004	10,82 miljardi undefined	121,00 milj. undefined	90,00 milj. undefined

	Apgrozījums	EBIT	Peļņa
2004	10,82 miljardi CNY	121,00 milj. CNY	90,00 milj. CNY
2005	10,70 miljardi CNY	90,00 milj. CNY	51,00 milj. CNY
2006	12,64 miljardi CNY	120,00 milj. CNY	-39,00 milj. CNY
2007	13,92 miljardi CNY	220,00 milj. CNY	66,00 milj. CNY
2008	16,55 miljardi CNY	208,00 milj. CNY	82,00 milj. CNY
2009	31,26 miljardi CNY	1,28 miljardi CNY	1,30 miljardi CNY
2010	38,53 miljardi CNY	1,76 miljardi CNY	1,27 miljardi CNY
2011	54,90 miljardi CNY	2,34 miljardi CNY	2,04 miljardi CNY
2012	68,08 miljardi CNY	2,55 miljardi CNY	2,05 miljardi CNY
2013	78,22 miljardi CNY	2,79 miljardi CNY	2,24 miljardi CNY
2014	92,40 miljardi CNY	3,21 miljardi CNY	2,59 miljardi CNY
2015	105,52 miljardi CNY	3,62 miljardi CNY	2,88 miljardi CNY
2016	120,77 miljardi CNY	3,74 miljardi CNY	3,20 miljardi CNY
2017	130,85 miljardi CNY	5,06 miljardi CNY	3,52 miljardi CNY
2018	159,08 miljardi CNY	5,71 miljardi CNY	3,88 miljardi CNY
2019	186,57 miljardi CNY	7,37 miljardi CNY	4,08 miljardi CNY
2020	191,91 miljardi CNY	7,74 miljardi CNY	4,50 miljardi CNY
2021	215,82 miljardi CNY	7,80 miljardi CNY	5,09 miljardi CNY
2022	231,98 miljardi CNY	8,32 miljardi CNY	5,62 miljardi CNY
2023	260,30 miljardi CNY	8,86 miljardi CNY	3,77 miljardi CNY
2024e	291,16 miljardi CNY	9,86 miljardi CNY	2,70 miljardi CNY
2025e	322,76 miljardi CNY	11,21 miljardi CNY	3,04 miljardi CNY
2026e	357,23 miljardi CNY	12,63 miljardi CNY	3,50 miljardi CNY

Shanghai Pharmaceuticals Holding Co Brutomarža	Shanghai Pharmaceuticals Holding Co Peļņas marge	Shanghai Pharmaceuticals Holding Co EBIT marža	Shanghai Pharmaceuticals Holding Co Peļņas marge
2026e	11,92 %	3,54 %	0,98 %
2025e	11,92 %	3,47 %	0,94 %
2024e	11,92 %	3,39 %	0,93 %
2023	11,92 %	3,40 %	1,45 %
2022	13,14 %	3,58 %	2,42 %
2021	13,20 %	3,61 %	2,36 %
2020	14,09 %	4,03 %	2,34 %
2019	14,22 %	3,95 %	2,19 %
2018	13,96 %	3,59 %	2,44 %
2017	12,73 %	3,87 %	2,69 %
2016	11,73 %	3,10 %	2,65 %
2015	11,92 %	3,43 %	2,73 %
2014	12,24 %	3,48 %	2,80 %
2013	12,98 %	3,56 %	2,87 %
2012	13,56 %	3,75 %	3,02 %
2011	14,31 %	4,25 %	3,72 %
2010	17,71 %	4,57 %	3,29 %
2009	18,71 %	4,08 %	4,15 %
2008	8,60 %	1,26 %	0,50 %
2007	8,63 %	1,58 %	0,47 %
2006	8,26 %	0,95 %	-0,31 %
2005	6,41 %	0,84 %	0,48 %
2004	9,24 %	1,12 %	0,83 %

	Brutomarža	EBIT marža	Peļņas marge
2004	9,24 %	1,12 %	0,83 %
2005	6,41 %	0,84 %	0,48 %
2006	8,26 %	0,95 %	-0,31 %
2007	8,63 %	1,58 %	0,47 %
2008	8,60 %	1,26 %	0,50 %
2009	18,71 %	4,08 %	4,15 %
2010	17,71 %	4,57 %	3,29 %
2011	14,31 %	4,25 %	3,72 %
2012	13,56 %	3,75 %	3,02 %
2013	12,98 %	3,56 %	2,87 %
2014	12,24 %	3,48 %	2,80 %
2015	11,92 %	3,43 %	2,73 %
2016	11,73 %	3,10 %	2,65 %
2017	12,73 %	3,87 %	2,69 %
2018	13,96 %	3,59 %	2,44 %
2019	14,22 %	3,95 %	2,19 %
2020	14,09 %	4,03 %	2,34 %
2021	13,20 %	3,61 %	2,36 %
2022	13,14 %	3,58 %	2,42 %
2023	11,92 %	3,40 %	1,45 %
2024e	11,92 %	3,39 %	0,93 %
2025e	11,92 %	3,47 %	0,94 %
2026e	11,92 %	3,54 %	0,98 %

Datums	Shanghai Pharmaceuticals Holding Co Apgrozījums uz vienu akciju	Shanghai Pharmaceuticals Holding Co EBIT uz vienu akciju	Shanghai Pharmaceuticals Holding Co Peļņa uz vienu akciju
2026e	184,95 undefined	0 undefined	1,81 undefined
2025e	167,10 undefined	0 undefined	1,57 undefined
2024e	150,74 undefined	0 undefined	1,40 undefined
2023	70,33 undefined	2,39 undefined	1,02 undefined
2022	66,61 undefined	2,39 undefined	1,61 undefined
2021	75,85 undefined	2,74 undefined	1,79 undefined
2020	67,43 undefined	2,72 undefined	1,58 undefined
2019	65,83 undefined	2,60 undefined	1,44 undefined
2018	56,23 undefined	2,02 undefined	1,37 undefined
2017	48,66 undefined	1,88 undefined	1,31 undefined
2016	44,91 undefined	1,39 undefined	1,19 undefined
2015	39,24 undefined	1,35 undefined	1,07 undefined
2014	34,36 undefined	1,19 undefined	0,96 undefined
2013	29,09 undefined	1,04 undefined	0,83 undefined
2012	25,32 undefined	0,95 undefined	0,76 undefined
2011	22,68 undefined	0,96 undefined	0,84 undefined
2010	19,33 undefined	0,88 undefined	0,64 undefined
2009	15,69 undefined	0,64 undefined	0,65 undefined
2008	29,08 undefined	0,37 undefined	0,14 undefined
2007	24,46 undefined	0,39 undefined	0,12 undefined
2006	22,21 undefined	0,21 undefined	-0,07 undefined
2005	18,80 undefined	0,16 undefined	0,09 undefined
2004	19,01 undefined	0,21 undefined	0,16 undefined

	Apgrozījums uz vienu akciju	EBIT uz vienu akciju	Peļņa uz vienu akciju
2004	19,01 CNY	0,21 CNY	0,16 CNY
2005	18,80 CNY	0,16 CNY	0,09 CNY
2006	22,21 CNY	0,21 CNY	-0,07 CNY
2007	24,46 CNY	0,39 CNY	0,12 CNY
2008	29,08 CNY	0,37 CNY	0,14 CNY
2009	15,69 CNY	0,64 CNY	0,65 CNY
2010	19,33 CNY	0,88 CNY	0,64 CNY
2011	22,68 CNY	0,96 CNY	0,84 CNY
2012	25,32 CNY	0,95 CNY	0,76 CNY
2013	29,09 CNY	1,04 CNY	0,83 CNY
2014	34,36 CNY	1,19 CNY	0,96 CNY
2015	39,24 CNY	1,35 CNY	1,07 CNY
2016	44,91 CNY	1,39 CNY	1,19 CNY
2017	48,66 CNY	1,88 CNY	1,31 CNY
2018	56,23 CNY	2,02 CNY	1,37 CNY
2019	65,83 CNY	2,60 CNY	1,44 CNY
2020	67,43 CNY	2,72 CNY	1,58 CNY
2021	75,85 CNY	2,74 CNY	1,79 CNY
2022	66,61 CNY	2,39 CNY	1,61 CNY
2023	70,33 CNY	2,39 CNY	1,02 CNY
2024e	150,74 CNY	0 CNY	1,40 CNY
2025e	167,10 CNY	0 CNY	1,57 CNY
2026e	184,95 CNY	0 CNY	1,81 CNY

	Akciju skaits
2004	569,00 milj. Aktien
2005	569,00 milj. Aktien
2006	569,00 milj. Aktien
2007	569,00 milj. Aktien
2008	569,00 milj. Aktien
2009	1,99 miljardi Aktien
2010	1,99 miljardi Aktien
2011	2,42 miljardi Aktien
2012	2,69 miljardi Aktien
2013	2,69 miljardi Aktien
2014	2,69 miljardi Aktien
2015	2,69 miljardi Aktien
2016	2,69 miljardi Aktien
2017	2,69 miljardi Aktien
2018	2,83 miljardi Aktien
2019	2,83 miljardi Aktien
2020	2,85 miljardi Aktien
2021	2,85 miljardi Aktien
2022	3,48 miljardi Aktien
2023	3,70 miljardi Aktien
2024e	3,70 miljardi Aktien
2025e	3,70 miljardi Aktien
2026e	3,70 miljardi Aktien

Datums	Shanghai Pharmaceuticals Holding Co Dividende
2026e	0,65 undefined
2025e	0,65 undefined
2024e	0,65 undefined
2023	0,61 undefined
2022	0,42 undefined
2021	0,48 undefined
2020	0,44 undefined
2019	0,41 undefined
2018	0,38 undefined
2017	0,36 undefined
2016	0,33 undefined
2015	0,29 undefined
2014	0,26 undefined
2013	0,24 undefined
2012	0,16 undefined
2011	0,14 undefined
2010	0,10 undefined
2009	0,05 undefined
2008	0,05 undefined
2006	0,10 undefined
2005	0,07 undefined
2004	0,07 undefined

	Dividende	Dividende (prognoze)
2004	0,07 CNY	0 CNY
2005	0,07 CNY	0 CNY
2006	0,10 CNY	0 CNY
2007	0 CNY	0 CNY
2008	0,05 CNY	0 CNY
2009	0,05 CNY	0 CNY
2010	0,10 CNY	0 CNY
2011	0,14 CNY	0 CNY
2012	0,16 CNY	0 CNY
2013	0,24 CNY	0 CNY
2014	0,26 CNY	0 CNY
2015	0,29 CNY	0 CNY
2016	0,33 CNY	0 CNY
2017	0,36 CNY	0 CNY
2018	0,38 CNY	0 CNY
2019	0,41 CNY	0 CNY
2020	0,44 CNY	0 CNY
2021	0,48 CNY	0 CNY
2022	0,42 CNY	0 CNY
2023	0,61 CNY	0 CNY
2024e	0 CNY	0,65 CNY
2025e	0 CNY	0,65 CNY
2026e	0 CNY	0,65 CNY

Datums	Shanghai Pharmaceuticals Holding Co Izplatīšanas likme
2026e	26,67 %
2025e	26,51 %
2024e	26,59 %
2023	26,90 %
2022	26,04 %
2021	26,82 %
2020	27,85 %
2019	28,47 %
2018	27,74 %
2017	27,48 %
2016	27,73 %
2015	27,10 %
2014	27,08 %
2013	28,92 %
2012	21,05 %
2011	16,67 %
2010	15,94 %
2009	6,92 %
2008	35,71 %
2007	26,90 %
2006	-148,81 %
2005	74,07 %
2004	46,87 %

	Izplatīšanas likme
2004	46,87 %
2005	74,07 %
2006	-148,81 %
2007	26,90 %
2008	35,71 %
2009	6,92 %
2010	15,94 %
2011	16,67 %
2012	21,05 %
2013	28,92 %
2014	27,08 %
2015	27,10 %
2016	27,73 %
2017	27,48 %
2018	27,74 %
2019	28,47 %
2020	27,85 %
2021	26,82 %
2022	26,04 %
2023	26,90 %
2024e	26,59 %
2025e	26,51 %
2026e	26,67 %

Datums	EPS-prognoze	EPS-Faktiskais	Ziņojuma ceturksnis
31.03.2024.	1,53	0,42 (-72,63 %)	2024 Q1
31.12.2023.	0,53	-0,01 (-101,90 %)	2023 Q4
30.09.2023.	0,45	0,32 (-29,59 %)	2023 Q3
30.06.2023.	0,65	0,30 (-53,59 %)	2023 Q2
31.03.2023.	0,40	0,41 (1,49 %)	2023 Q1
31.12.2022.	-0,29	0,16 (154,63 %)	2022 Q4
30.09.2022.	0,36	0,30 (-17,49 %)	2022 Q3
30.06.2022.	0,45	0,66 (45,46 %)	2022 Q2
31.03.2022.	0,57	0,44 (-22,21 %)	2022 Q1
31.12.2021.	0,24	0,21 (-13,37 %)	2021 Q4
30.09.2021.	0,53	0,32 (-39,07 %)	2021 Q3
30.06.2021.	0,68	0,51 (-24,17 %)	2021 Q2
31.03.2021.	0,51	0,75 (48,51 %)	2021 Q1
31.12.2020.	0,40	0,31 (-23,27 %)	2020 Q4
30.09.2020.	0,26	0,41 (56,13 %)	2020 Q3
30.06.2020.	0,45	0,49 (7,81 %)	2020 Q2
31.03.2020.	0,38	0,37 (-1,52 %)	2020 Q1
31.12.2019.	0,36	0,24 (-32,71 %)	2019 Q4
30.09.2019.	0,37	0,39 (6,18 %)	2019 Q3
30.06.2019.	0,41	0,41 (-0,23 %)	2019 Q2
31.03.2019.	0,41	0,40 (-4,30 %)	2019 Q1
31.12.2018.	0,30	0,18 (-39,93 %)	2018 Q4
30.09.2018.	0,31	0,47 (51,33 %)	2018 Q3
30.06.2018.	0,29	0,36 (21,54 %)	2018 Q2
31.03.2018.	0,37	0,37 (-2,19 %)	2018 Q1
31.12.2017.	0,30	0,31 (1,54 %)	2017 Q4
30.09.2017.	0,29	0,28 (-2,20 %)	2017 Q3
30.06.2017.	0,46	0,34 (-25,36 %)	2017 Q2
31.03.2017.	0,34	0,37 (7,93 %)	2017 Q1
31.12.2016.	0,30	0,27 (-7,84 %)	2016 Q4
30.09.2016.	0,29	0,27 (-5,97 %)	2016 Q3
30.06.2016.	0,32	0,31 (-3,08 %)	2016 Q2
31.03.2016.	0,28	0,33 (18,52 %)	2016 Q1
31.12.2015.	0,28	0,26 (-8,19 %)	2015 Q4
30.09.2015.	0,26	0,24 (-7,09 %)	2015 Q3
30.06.2015.	0,32	0,30 (-8,19 %)	2015 Q2
31.03.2015.	0,26	0,27 (3,96 %)	2015 Q1
31.12.2014.	0,22	0,25 (14,96 %)	2014 Q4
30.09.2014.	0,22	0,22 (1,05 %)	2014 Q3
30.06.2014.	0,27	0,27 (-0,93 %)	2014 Q2
31.03.2014.	0,24	0,22 (-10,80 %)	2014 Q1
31.12.2013.	0,21	0,21 (-1,92 %)	2013 Q4
30.09.2013.	0,22	0,18 (-15,78 %)	2013 Q3
30.06.2013.	0,22	0,21 (-5,52 %)	2013 Q2
31.12.2012.	0,18	0,19 (2,27 %)	2012 Q4
30.09.2011.	0,19	0,15 (-20,27 %)	2011 Q3
30.06.2011.	0,21	0,06 (-72,18 %)	2011 Q2

%	Nosaukums	Akcijas	Izmaiņas	Datums
37,10 %	Shanghai Pharmaceutical (Group) Co. Ltd.	716 516 039	0	31.12.2023.
34,46 %	Yunnan Baiyao Group Co., Ltd.	665 626 796	0	31.12.2023.
32,62 %	Shanghai Industrial Investment (Holdings) Co., Ltd.	629 987 798	220 686 000	31.12.2023.
2,31 %	Shanghai Guosheng (Group) Co., Ltd.	44 632 100	23 762 800	31.12.2023.
1,12 %	Yinhua Fund Management Co., Ltd.	21 712 597	10 111 375	31.12.2023.
0,87 %	E Fund Management Co. Ltd.	16 734 637	-784 660	31.12.2023.
0,64 %	Orient Securities Asset Management Company Limited	12 449 700	12 449 700	30.06.2023.
0,57 %	Fullgoal Fund Management Co., Ltd.	11 000 000	118 000	31.12.2023.
0,56 %	China Universal Asset Management Co., Ltd.	10 839 871	-1 102 100	31.12.2023.
0,46 %	Huatai-PineBridge Fund Management Co., Ltd.	8 874 912	4 450 669	31.12.2023.
0,46 %	China Southern Asset Management Co. Ltd.	8 860 445	-5800	31.12.2023.
0,46 %	GF Fund Management Co., Ltd.	8 801 380	-2 289 400	31.12.2023.
0,44 %	Norges Bank Investment Management (NBIM)	8 406 130	-445 828	31.12.2023.
0,36 %	Lion Fund Management Co., Ltd.	6 997 832	-169 000	31.12.2023.
0,29 %	The Vanguard Group, Inc.	5 613 896	0	31.03.2024.
0,29 %	BlackRock Institutional Trust Company, N.A.	5 571 831	-51 300	31.03.2024.
0,27 %	China Asset Management Co., Ltd.	5 254 667	946 805	31.12.2023.
0,20 %	HuaAn Fund Management Co., Ltd.	3 845 988	-352 900	31.12.2023.
0,18 %	INVESCO Great Wall Fund Management Co. Ltd.	3 495 355	-11 000	31.12.2023.
0,17 %	BlackRock Advisors (UK) Limited	3 350 579	116 000	31.03.2024.
0,16 %	Wellington Management Company, LLP	3 134 300	252 100	29.02.2024.
0,13 %	CIB Fund Management Co., Ltd.	2 568 900	-59 700	31.12.2023.
0,12 %	Huashang Fund Management Co., Ltd.	2 258 756	2 258 756	31.12.2023.
0,11 %	Franklin Templeton Sealand Fund Management Co., Ltd.	2 054 100	-20 800	31.12.2023.
0,10 %	BlackRock Investment Management, LLC	2 024 760	178 600	31.12.2023.
0,09 %	Tianhong Asset Management Co., Ltd.	1 739 387	-4300	31.12.2023.
0,09 %	Charles Schwab Investment Management, Inc.	1 693 400	1 421 900	31.03.2024.
0,08 %	Purekind Fund Management Co., Ltd.	1 500 010	870 010	30.06.2023.
0,07 %	HSBC JinTrust Fund Management Co., Ltd.	1 392 100	-1 060 759	31.12.2023.
0,07 %	Harvest Fund Management Co., Ltd.	1 373 328	0	29.02.2024.
0,06 %	Geode Capital Management, L.L.C.	1 249 500	3200	29.02.2024.
0,06 %	Penghua Fund Management Co., Ltd.	1 227 500	972 700	30.06.2023.
0,05 %	Guotai Junan Securities Assets Management Co., Ltd.	1 003 200	-66 200	30.06.2023.
0,05 %	China Merchants Fund Management Co. Ltd.	974 217	36 800	31.12.2023.
0,05 %	Bosera Asset Management Co., Ltd.	872 100	816 700	31.12.2023.
0,04 %	Harvest Global Investments Limited	867 550	0	31.03.2024.
0,04 %	BOC International (China) Ltd.	750 000	-50 000	31.12.2023.
0,04 %	China Asset Management (Hong Kong) Limited	739 600	49 200	31.03.2024.
0,04 %	Caitong Securities Asset Management Co., Ltd.	706 400	706 400	30.06.2023.
0,04 %	DWS Investments UK Limited	693 169	-3145	31.03.2024.
0,04 %	Guotai Asset Management Co., Ltd.	686 108	25 500	31.12.2023.
0,04 %	Hwabao WP Fund Management Co., Ltd.	679 800	-7400	31.12.2023.
0,03 %	BlackRock Financial Management, Inc.	671 700	589 400	31.10.2023.
0,03 %	Rongtong Fund Management Co., Ltd.	646 000	646 000	30.06.2023.
0,03 %	Everbright PGIM Fund Management Co., Ltd.	596 000	596 000	30.06.2023.
0,03 %	Zheshang Fund Management Co., Ltd.	591 600	-552 438	31.12.2023.
0,03 %	State Street Global Advisors (US)	567 479	326	29.02.2024.
0,03 %	Changsheng Fund Management Co., Ltd.	539 337	0	31.12.2023.
0,02 %	Focusbridge Investments Limited	475 000	475 000	30.06.2023.
0,02 %	SWS MU Fund Management Co., Ltd.	467 524	290 000	31.12.2023.
0,02 %	Swedbank Robur Fonder AB	467 300	0	29.02.2024.
0,02 %	Aviva Investors Global Services Limited	422 396	164 266	29.02.2024.
0,02 %	UBS Asset Management (UK) Ltd.	415 705	1400	31.03.2024.
0,02 %	Chang Xin Asset Management Co., Ltd.	399 700	57 100	31.12.2023.
0,02 %	BlackRock (Singapore) Limited	390 914	92 900	31.03.2024.
0,02 %	Amundi Asset Management, SAS	388 600	-88 600	31.03.2024.
0,02 %	BlackRock Asset Management North Asia Limited	381 600	0	31.12.2023.
0,02 %	Credit Suisse Funds AG	325 700	-6600	31.03.2024.
0,02 %	UBS Asset Management (Switzerland)	320 700	0	29.02.2024.
0,02 %	Northern Trust Global Investments Limited	310 600	30 500	29.02.2024.
0,02 %	California State Teachers Retirement System	304 100	103 400	30.06.2023.
0,02 %	Taiping Fund Management Co., Ltd.	292 900	292 900	30.06.2023.
0,01 %	State Street Global Advisors (UK) Ltd.	268 410	1	31.03.2024.
0,01 %	CCB Principal Asset Management Co., Ltd.	250 654	-358 300	31.12.2023.
0,01 %	JPMorgan Asset Management (China) Company Limited.	245 300	25 600	30.06.2023.
0,01 %	First-Trust Fund Management Co., Ltd.	236 200	0	31.12.2023.
0,01 %	Fuanda Fund Management Co., Ltd.	233 000	-47 500	31.12.2023.
0,01 %	BlackRock Investment Management (UK) Ltd.	232 100	0	29.02.2024.
0,01 %	Krane Funds Advisors, LLC	229 694	5700	31.03.2024.
0,01 %	Wilmington Trust Investment Management LLC	222 800	0	29.02.2024.
0,01 %	Nuveen LLC	221 732	0	31.03.2024.
0,01 %	Taikang Asset Management Co., Ltd.	212 300	200 100	30.06.2023.
0,01 %	Tibet Eastmoney Fund Management Co., Ltd.	210 900	-22 700	31.12.2023.
0,01 %	DWS Investment GmbH	202 802	-5400	31.03.2024.
0,01 %	CPIC Fund Management Co., Ltd.	196 746	-3300	31.12.2023.
0,01 %	HSBC Global Asset Management (UK) Limited	195 347	0	29.02.2024.
0,01 %	Goldman Sachs Asset Management, L.P.	193 614	-5802	31.03.2024.
0,01 %	HFT Investment Management Co., Ltd.	164 200	-1800	31.12.2023.
0,01 %	Amundi Japan Ltd.	138 400	-5400	31.03.2024.
0,01 %	Mercer Global Investments Management Ltd	136 700	0	31.03.2024.
0,01 %	Invesco Capital Management LLC	136 570	0	31.03.2024.
0,01 %	Fubon Asset Management Company Ltd.	117 854	-10 600	29.02.2024.
0,01 %	Zürcher Kantonalbank (Asset Management)	117 400	0	29.02.2024.
0,01 %	Handelsbanken Kapitalförvaltning AB	112 500	0	31.03.2024.
0,01 %	Pictet Asset Management Ltd.	112 300	-8200	31.12.2023.
0,01 %	Legal & General Investment Management Ltd.	111 130	0	29.02.2024.
0,01 %	Truvalue Asset Management Co., Ltd.	106 900	106 900	30.06.2023.
0,01 %	HSBC Global Asset Management (Hong Kong) Limited	102 745	-522 900	31.12.2023.
0,01 %	BOCI-Prudential Asset Management Ltd.	100 915	800	29.02.2024.
0,01 %	China Fund Management Co., Ltd.	100 000	-87 100	30.06.2023.
0,01 %	Maxwealth Fund Management Co., Ltd.	98 800	91 600	30.06.2023.
0,00 %	BMO Asset Management Inc.	86 236	0	31.03.2024.
0,00 %	Wanjia Asset Management Co., Ltd.	85 981	-2000	31.12.2023.
0,00 %	China Life AMP Asset Management Co., Ltd	84 000	-2000	31.12.2023.
0,00 %	WCM Investment Management	83 700	-13 900	31.12.2023.
0,00 %	JT Asset Management Co., Ltd.	82 500	78 300	30.06.2023.
0,00 %	ABC-CA Fund Management Co., Ltd.	82 100	-110 300	31.12.2023.
0,00 %	Cardano Asset Management NV	74 491	7	29.02.2024.
0,00 %	Ping An Fund Management Company Limited	72 800	700	31.12.2023.
0,00 %	Shen (Bo)	71 700	0	31.12.2023.

Vārds	attiecības	Divnedēļu korelācija	Vienmēneša korelācija	Trīs mēnešu korelācija	Sešu mēnešu korelācija	Viena gada korelācija	Divu gadu korelācija
Shenzhen Chipscreen Biosciences A	PiegādātājsKlients	0,99	0,84	-0,03	-0,30	-	0,07
Shandong Wohua Pharm	PiegādātājsKlients	0,99	0,92	0,68	0,59	0,66	0,28
Gan & Lee Pharmaceuticals A	PiegādātājsKlients	0,97	0,92	0,09	-0,21	0,42	-
Shanghai Jiao Yun Gp A	PiegādātājsKlients	0,97	0,56	0,61	0,65	0,64	0,39
Super Telecom A	PiegādātājsKlients	0,97	0,93	0,80	0,18	0,27	-
Betta Pharmaceuticals A	PiegādātājsKlients	0,96	0,97	0,18	-0,25	0,21	0,15
Essence Info A	PiegādātājsKlients	0,95	0,93	-0,14	-0,14	0,12	-
Shanghai Haixin Group A	PiegādātājsKlients	0,94	0,76	0,33	-0,07	-0,07	0,08
Enzymatica	PiegādātājsKlients	0,93	0,76	0,53	-0,14	0,12	0,08
Greenland -A-	PiegādātājsKlients	0,90	0,89	0,41	0,52	0,68	-

What values and corporate philosophy does Shanghai Pharmaceuticals Holding Co represent?

Shanghai Pharmaceuticals Holding Co Ltd embodies a set of values and a corporate philosophy that underpin its operations. The company believes in delivering high-quality healthcare products and services to meet the evolving needs of its customers. Shanghai Pharmaceuticals focuses on fostering innovation, maintaining integrity, and ensuring sustainable development. By prioritizing the well-being of patients and healthcare professionals, the company strives to enhance public health and contribute to society. Shanghai Pharmaceuticals' commitment to improving medical access and advancing healthcare systems reflects its dedication to delivering value and making a positive impact in the pharmaceutical industry.

In which countries and regions is Shanghai Pharmaceuticals Holding Co primarily present?

Shanghai Pharmaceuticals Holding Co Ltd operates primarily in China. As a leading pharmaceutical company based in Shanghai, China, it has established a strong presence in its home country. With an extensive network and many subsidiaries across China, Shanghai Pharmaceuticals Holding Co Ltd serves a vast market within the country. Its presence and influence in the Chinese pharmaceutical industry contribute to its position as a key player in the region.

What significant milestones has the company Shanghai Pharmaceuticals Holding Co achieved?

Shanghai Pharmaceuticals Holding Co Ltd has achieved several significant milestones in its corporate history. The company has successfully established itself as a leading player in the pharmaceutical sector in China. Shanghai Pharmaceuticals Holding Co Ltd has expanded its business operations both domestically and internationally, through strategic acquisitions and partnerships. The company has demonstrated continued growth and stability, with a diversified product portfolio and a strong presence in key therapeutic areas. Shanghai Pharmaceuticals Holding Co Ltd has consistently focused on innovation, research and development, and delivering high-quality healthcare products and services. Through its continuous efforts, the company has garnered recognition and trust from both investors and consumers alike.

What is the history and background of the company Shanghai Pharmaceuticals Holding Co?

Shanghai Pharmaceuticals Holding Co Ltd, established in 1994, is a renowned Chinese pharmaceutical company. With its headquarters in Shanghai, the company has a rich history and exceptional background in the healthcare industry. Shanghai Pharmaceuticals operates across various segments, including the production, distribution, and retail of pharmaceutical and healthcare products. Over the years, it has expanded its business both domestically and internationally, becoming a leading player in China's pharmaceutical market. With a strong focus on research and development, Shanghai Pharmaceuticals has established strategic partnerships and collaborations with global pharmaceutical giants, further enhancing its position in the industry. This company's commitment to innovation, quality, and customer satisfaction has contributed to its success and widespread recognition.

Who are the main competitors of Shanghai Pharmaceuticals Holding Co in the market?

Some of the main competitors of Shanghai Pharmaceuticals Holding Co Ltd in the market include China Resources Pharmaceutical Group Limited, Jiangsu Hengrui Medicine Co Ltd, and Sinopharm Group Co Ltd.

In which industries is Shanghai Pharmaceuticals Holding Co primarily active?

Shanghai Pharmaceuticals Holding Co Ltd is primarily active in the pharmaceutical industry. As one of the leading pharmaceutical companies in China, it operates in various sectors including research and development, manufacturing, distribution, and retail. With a diversified product portfolio, Shanghai Pharmaceuticals caters to a wide range of healthcare needs, including prescription drugs, over-the-counter medications, traditional Chinese medicine, medical devices, and healthcare services. The company's strong presence and expertise in the pharmaceutical industry enable it to contribute significantly to the advancement of healthcare and improve the quality of life for individuals across China and beyond.

What is the business model of Shanghai Pharmaceuticals Holding Co?

The business model of Shanghai Pharmaceuticals Holding Co Ltd is focused on pharmaceutical production, distribution, and retail sales. As one of China's leading integrated pharmaceutical companies, Shanghai Pharmaceuticals engages in research and development, manufacturing, marketing, and sales of both innovative and generic drugs. The company operates a comprehensive supply chain, including procurement, distribution, and retailing services. By combining its strong domestic presence with international expansion, Shanghai Pharmaceuticals aims to deliver high quality and affordable healthcare products to improve public health in China and beyond.

Kāds ir Shanghai Pharmaceuticals Holding Co 2024 KGV?

Shanghai Pharmaceuticals Holding Co KGV ir 26,41.

Kāds ir Shanghai Pharmaceuticals Holding Co 2024 KUV?

Shanghai Pharmaceuticals Holding Co KUV ir 0,24.

Kāds AlleAktien kvalitātes vērtējums ir Shanghai Pharmaceuticals Holding Co?

AlleAktien kvalitātes vērtējums Shanghai Pharmaceuticals Holding Co ir 7/10.

Cik liels ir Shanghai Pharmaceuticals Holding Co 2024 apgrozījums?

gaidāmā Shanghai Pharmaceuticals Holding Co apgrozījums ir 291,16 miljardi CNY.

Cik liels ir Shanghai Pharmaceuticals Holding Co 2024 peļņa?

gaidāmā Shanghai Pharmaceuticals Holding Co peļņa ir 2,70 miljardi CNY.

Kas ir Shanghai Pharmaceuticals Holding Co?

Shanghai Pharmaceuticals Holding Co Ltd is a leading Chinese pharmaceutical conglomerate that was founded in 1994. The company is headquartered in Shanghai and consists of various divisions, including pharmaceutical manufacturing, medication distribution, research and development, and chemical production. The company offers a wide range of products that are used in various fields of medicine. This includes antidepressants, analgesics, antipyretics, cardiology, and oncology. Additionally, the company also provides traditional Chinese medicine products and medical accessories. The pharmaceutical production division is one of the most important for the company. Here, Shanghai Pharmaceuticals produces a wide range of pharmaceuticals, including generics and patented products. The company has a strong research and development department specialized in producing highly effective drugs for various medical conditions. Another important area for the company is medication distribution. The company has a network of distribution partners that help distribute the products to different countries and regions. Shanghai Pharmaceuticals has branches in many countries and regions, including Thailand, Australia, and the USA. The company also has a strong presence in traditional Chinese medicine and offers a variety of products, including herbal blends and herbal capsules. These products have been used in Chinese culture for thousands of years and are popular among people worldwide. Shanghai Pharmaceuticals also has its own research and development department that is involved in the development of some very important drugs. The company specializes in developing drugs for chronic diseases such as diabetes, cancer, and cardiovascular diseases. In addition to pharmaceutical production, the company also offers some chemical products. Shanghai Pharmaceuticals manufactures various chemicals such as intermediates used in the pharmaceutical industry. These products are often used as raw materials for drug manufacturing. Overall, Shanghai Pharmaceuticals' business model is very successful, and the company is one of the leading Chinese companies in the pharmaceutical industry. The company has established itself as a reliable partner for various medical products and services, and is expected to continue growing in the future.

Cik liela ir Shanghai Pharmaceuticals Holding Co dividende?

Shanghai Pharmaceuticals Holding Co izmaksā dividendes 0,42 CNY, kas tiek izmaksātas reizes gadā.

Cik bieži Shanghai Pharmaceuticals Holding Co maksā dividendes?

Dividendes pašlaik nevar aprēķināt Shanghai Pharmaceuticals Holding Co vai uzņēmums nedod dividendes.

Kas ir Shanghai Pharmaceuticals Holding Co ISIN?

Shanghai Pharmaceuticals Holding Co ISIN ir CNE000000C82.

Kas ir Shanghai Pharmaceuticals Holding Co biržas kods?

Shanghai Pharmaceuticals Holding Co simbols ir 601607.SS.

Cik lielu dividendēm maksā Shanghai Pharmaceuticals Holding Co?

Pēdējo 12 mēnešu laikā Shanghai Pharmaceuticals Holding Co maksāja dividendes 0,61 CNY apmērā. Tas atbilst aptuveni 3,17 % dividendes ražībai. Nākamajos 12 mēnešos Shanghai Pharmaceuticals Holding Co plāno maksāt dividendes 0,65 CNY apmērā.

Cik augsta ir Shanghai Pharmaceuticals Holding Co dividendu rentabilitāte?

Shanghai Pharmaceuticals Holding Co pašreizējā dividendu rentabilitāte ir 3,17 %.

Kad Shanghai Pharmaceuticals Holding Co maksā dividendes?

Shanghai Pharmaceuticals Holding Co maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos augusts, augusts, augusts, augusts.

Cik droša ir Shanghai Pharmaceuticals Holding Co dividende?

Shanghai Pharmaceuticals Holding Co pēdējo 19 gadu laikā katru gadu izmaksāja dividendes.

Cik liela ir Shanghai Pharmaceuticals Holding Co dividende?

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0,65 CNY. Tas atbilst dividendes ražībai 3,36 %.

Kurā sektorā atrodas Shanghai Pharmaceuticals Holding Co?

Shanghai Pharmaceuticals Holding Co tiek piešķirts nozarei "Veselība".

Wann musste ich die Aktien von Shanghai Pharmaceuticals Holding Co kaufen, um die vorherige Dividende zu erhalten?

Lai saņemtu pēdējo dividendu Shanghai Pharmaceuticals Holding Co apmērā 0,61 CNY, kas tika izmaksāta 20.07.2023., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 20.07.2023..

Kad Shanghai Pharmaceuticals Holding Co izmaksāja pēdējo dividendē?

Pēdējās dividendes izmaksa notika 20.07.2023..

Cik liela bija Shanghai Pharmaceuticals Holding Co dividende gadā 2023?

Gadā 2023, Shanghai Pharmaceuticals Holding Co izmaksāja 0,42 CNY dividendes.

Kādā valūtā Shanghai Pharmaceuticals Holding Co izmaksā dividendes?

Shanghai Pharmaceuticals Holding Co dividendes tiek izmaksātas CNY.

1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5,62
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,71	2,28
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	164,00	-131,00
-73,00	-119,00	-213,00	-312,00	-106,00	-373,00	-179,00	-445,00	-453,00	-373,00	-1869,00	-1981,00	-2500,00	-6182,00	-6961,00	-7413,00	-8736,00	-9641,00	-10 469,00	-15 349,00	-16 387,00	-17 141,00	-18 394,00	-17 530,00
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
-31,00	-31,00	-108,00	-261,00	-238,00	-95,00	-90,00	-124,00	-240,00	-268,00	-1304,00	-1629,00	-2090,00	-2457,00	-2551,00	-2802,00	-3150,00	-3576,00	-3686,00	-5638,00	-5621,00	-5849,00	-6239,00	-8853,00
0,16	0,15	0,07	0,10	0	0,06	0,07	0,63	0,49	0,29	1,91	2,21	1,77	1,15	0,97	1,34	1,35	1,95	2,65	3,14	6,02	6,84	5,06	4,74
-52,00	-141,00	-144,00	-279,00	-169,00	-254,00	-198,00	-180,00	-192,00	-90,00	-765,00	-573,00	-413,00	-708,00	-905,00	-1291,00	-1720,00	-2119,00	-2007,00	-1943,00	-2753,00	-3010,00	-4118,00	-2684,00
-225,00	-120,00	-202,00	-99,00	-404,00	-234,00	-275,00	-13,00	-173,00	349,00	287,00	-2988,00	-3790,00	-174,00	-892,00	-1844,00	-1908,00	-2889,00	-2355,00	-7692,00	-4584,00	-1705,00	-6015,00	-12 473,00
-0,17	0,02	-0,06	0,18	-0,24	0,02	-0,08	0,17	0,02	0,44	1,05	-2,42	-3,38	0,53	0,01	-0,55	-0,19	-0,77	-0,35	-5,75	-1,83	1,30	-1,90	-9,79
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0,31	0,27	-0,50	0,25	0,41	0,21	0,30	-0,25	-0,16	-0,04	-0,46	0,84	-1,40	-0,81	1,09	1,26	2,16	1,69	3,87	10,40	1,71	1,69	4,33	3,84
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
0,24	0,14	0,07	0,13	0,24	0,09	0,09	-0,40	-0,34	-0,27	-0,61	2,09	10,64	-2,25	-0,72	-0,95	0,64	0,65	2,31	7,53	-2,33	-1,26	1,57	12,14
-0,07	-0,06	0,63	0,00	0	0,01	0	-0,01	-0,02	-0,03	0,39	2,00	13,01	-0,28	-0,53	-0,63	0,10	0,67	0,47	-0,19	-1,45	-0,53	-0,09	11,40
0	-72,00	-49,00	-122,00	-166,00	-128,00	-210,00	-147,00	-154,00	-211,00	-537,00	-749,00	-969,00	-1157,00	-1284,00	-1576,00	-1628,00	-1712,00	-2032,00	-2677,00	-2584,00	-2418,00	-2675,00	-3093,00
0,44	0,46	0,33	0,81	0,19	0,45	0,23	1,42	1,16	1,29	6,68	7,13	14,71	8,54	9,83	10,10	13,32	14,87	19,39	27,16	27,14	33,70	30,26	35,52
112,20	5,10	-79,00	-178,60	-169,10	-192,70	-125,10	452,50	294,10	195,20	1145,80	1637,60	1358,90	441,90	68,30	44,20	-371,30	-172,60	641,50	1192,10	3269,30	3834,70	942,55	2058,50
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Tiešās emisijas	117 174,96
Nepārtrauktas emisijas no iegādātās enerģijas	333 124,49
Nepārtrauktas emisijas vērtību ķēdē	—
CO₂ emisijas	450 299,45
CO₂ samazināšanas stratēģija	✅
Oglekļa enerģija	❌
Atomenerģija	❌
Dzīvnieku izmēģinājumi	✅
Pelz & Leder	—
Pesticīdi	—
Palmas eļļa	—
Tabaka	❌
Ģenētiskā inženierija	❌
Klimata koncepcija	—
Ilgspējīga mežsaimniecība	—
Atkritumu pārstrādes noteikumi	✅
Videi draudzīga iepakojuma	✅
Bīstamās vielas	✅
Degvielas patēriņš un efektivitāte	❌
Ūdens patēriņš un efektivitāte	✅

Sieviešu īpatsvars darbinieku vidū	50,3
Sieviešu īpatsvars vadībā	—
Āzijas darbinieku īpatsvars	—
Āzijas vadības daļa	—
Hispano/latīņamerikāņu darbinieku īpatsvars	—
Hispano/latīņu pārstāvniecība vadībā	—
Akciju procentuālais daudzums melnādaino darbinieku vidū	—
Daļa melnādaino vadītāju	—
Baltie darbinieku īpatsvars	—
Baltie pārvaldības procenti	—
Pieaugušo satura	❌
Alkohols	❌
Aizsardzība	—
Ieroči	❌
Azartspēles	❌
Militārie līgumi	❌
Cilvēktiesību koncepcija	✅
Datumaizsardzības koncepcija	—
Darba aizsardzība un veselības aizsargāšana	✅
Katolisks	✅

Ilgtermiņa attīstības ziņojums	✅
Akciju turētāju iesaiste	✅
Atsaukšanas politika	❌
Kartel tiesības	❌

Shanghai Pharmaceuticals Holding Co Akciju biržas simbols	Shanghai Pharmaceuticals Holding Co FIGI
601607:CH	BBG000BKDQ46
601607:CG	BBG000BKDQG3
601607:C1	BBG00709JCF1

1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e
4,41	4,53	4,60	5,20	7,24	9,79	10,82	10,70	12,64	13,92	16,55	31,26	38,53	54,90	68,08	78,22	92,40	105,52	120,77	130,85	159,08	186,57	191,91	215,82	231,98	260,30	291,16	322,76	357,23
-	2,65	1,43	13,21	39,10	35,24	10,52	-1,07	18,13	10,14	18,88	88,91	23,26	42,48	24,00	14,90	18,12	14,20	14,45	8,35	21,58	17,28	2,86	12,46	7,49	12,21	11,86	10,86	10,68
11,67	12,05	12,67	13,40	13,93	10,16	9,24	6,41	8,26	8,63	8,60	18,71	17,71	14,31	13,56	12,98	12,24	11,92	11,73	12,73	13,96	14,22	14,09	13,20	13,14	11,92	-	-	-
0,52	0,55	0,58	0,70	1,01	0,99	1,00	0,69	1,04	1,20	1,42	5,85	6,83	7,86	9,23	10,15	11,31	12,57	14,16	16,66	22,21	26,52	27,04	28,49	30,48	31,02	0	0	0
0,13	0,18	0,18	0,17	0,19	0,16	0,12	0,09	0,12	0,22	0,21	1,28	1,76	2,34	2,55	2,79	3,21	3,62	3,74	5,06	5,71	7,37	7,74	7,80	8,32	8,86	9,86	11,21	12,63
2,95	4,00	3,83	3,33	2,64	1,61	1,12	0,84	0,95	1,58	1,26	4,08	4,57	4,25	3,75	3,56	3,48	3,43	3,10	3,87	3,59	3,95	4,03	3,61	3,58	3,40	3,39	3,47	3,54
0,06	0,09	0,16	0,14	0,13	0,14	0,09	0,05	-0,04	0,07	0,08	1,30	1,27	2,04	2,05	2,24	2,59	2,88	3,20	3,52	3,88	4,08	4,50	5,09	5,62	3,77	2,70	3,04	3,50
-	56,67	72,34	-11,73	-11,89	8,73	-34,31	-43,33	-176,47	-269,23	24,24	1481,71	-2,39	61,30	0,54	9,25	15,51	11,04	11,09	10,17	10,22	5,15	10,17	13,28	10,29	-32,92	-28,42	12,61	15,38
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
0,51	0,53	0,53	0,57	0,57	0,57	0,57	0,57	0,57	0,57	0,57	1,99	1,99	2,42	2,69	2,69	2,69	2,69	2,69	2,69	2,83	2,83	2,85	2,85	3,48	3,70	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Veic labākos ieguldījumus savā dzīvē

Kurss

Akciju cena

Simbols601607.SS

ISINCNE000000C82

Shanghai Pharmaceuticals Holding Co Akcijas apgrozījums, EBIT, peļņa CNE000000C82 ·

Apgrozījums, peļņa & EBIT

Apgrozījuma, EBIT un ienākumu izpratne

Gada analīze un salīdzinājumi

Ieguvumu izmantošana investīcijām

Ieguldījumu ieskati

Shanghai Pharmaceuticals Holding Co Apjoma, peļņas un EBIT vēsture

Shanghai Pharmaceuticals Holding Co Akciju Rādītāji

Peļņas un zaudējumu pārskats

Apjomi un izaugsme

Bruto marža

EBIT un EBIT marža

Ienākumi un izaugsme

Izlaistās akcijas

Gadskārtējās salīdzinājuma interpretācija

Gaidījumi un prognozes

Bilance

Bilances izpratne

Aktīvi

Parādsaistības

Pašu kapitāls

Gadu pēc gada analīze

Datu interpretācija

Shanghai Pharmaceuticals Holding Co akcijas maržas CNE000000C82 ·

Maržas

Brutomaržas izpratne

EBIT maržas analīze

Apjoma maržas ieskati

Gaidāmo vērtību interpretēšana

Salīdzinošā analīze

Shanghai Pharmaceuticals Holding Co Maržas vēsture

Shanghai Pharmaceuticals Holding Co akciju apgrozījums, EBIT, peļņa uz vienu akciju CNE000000C82 ·

Apjoms, EBIT un Peļņa uz vienu akciju

Apjoms uz vienu akciju

EBIT uz vienu akciju

Ienākumi uz vienu akciju

Gaidāmās vērtības

Shanghai Pharmaceuticals Holding Co Apjoma, peļņas un EBIT vēsture uz vienu akciju

Shanghai Pharmaceuticals Holding Co akcija un akciju analīze

Shanghai Pharmaceuticals Holding Co vērtējums pēc vēsturiskā PE, EBIT un P/S

Shanghai Pharmaceuticals Holding Co akciju skaits CNE000000C82 ·

Apjoms, EBIT un Peļņa uz vienu akciju

Apjoms uz vienu akciju

EBIT uz vienu akciju

Ienākumi uz vienu akciju

Gaidāmās vērtības

Shanghai Pharmaceuticals Holding Co Akciju spliti

Shanghai Pharmaceuticals Holding Co Akcijas Dividende CNE000000C82 ·

Dividende

Pārskats par dividendēm

Interpretācija un pielietojums

Investīciju stratēģija

Shanghai Pharmaceuticals Holding Co Dividendu vēsture

Shanghai Pharmaceuticals Holding Co Akciju izmaksu attiecība CNE000000C82 ·

Ausschüttungsquote

Kas ir gada izmaksu kvota?

Datu interpretācija

Datu izmantošana investīcijām

Shanghai Pharmaceuticals Holding Co Izplatīšanas kvotu vēsture

Shanghai Pharmaceuticals Holding Co Peļņas prognozes

Shanghai Pharmaceuticals Holding Co Pelnīguma Pārsteigumi

Eulerpool ESG reitings Shanghai Pharmaceuticals Holding Co akcijai

Eulerpool World ESG Rating (EESG©)

84/ 100

🌱 Environment

👫 Social

🏛️ Governance

Vide (Environment)

Sociālais

Uzņēmuma vadība (Governance)

Shanghai Pharmaceuticals Holding Co Akciju akcionāru struktūra

Shanghai Pharmaceuticals Holding Co Piegādes ķēde

Bieži uzdotie jautājumi par Shanghai Pharmaceuticals Holding Co akciju

What values and corporate philosophy does Shanghai Pharmaceuticals Holding Co represent?

In which countries and regions is Shanghai Pharmaceuticals Holding Co primarily present?

Simbols
601607.SS

ISIN
CNE000000C82